Vimarsana
Biggest News Aggregation in the World

Page 19 - Randomized Clinical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Randomized Clinical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Randomized Clinical Today - Breaking & Trending Today

Gundry MD Products Reviews 2023 - Dr. Gundry Products Test - Vimarsana News

Gundry MD Products Reviews 2023 - Dr. Gundry Products Test

Looking for the best Gundry MD products and supplements in 2023? Check out our Gundry MD reviews and find the best that they have to offer.

Intermittent Fasting And Diabetes 2023: Is It Good For Diabetics? - Vimarsana News

Intermittent Fasting And Diabetes 2023: Is It Good For Diabetics?

Do you wonder if intermittent fasting and diabetes have any relation and if it is good for diabetics. Read on to learn more about it in 2023.

Therapeutic Drug Monitoring May Be Future of Inflammatory Bowel Disease Management - Vimarsana News

Therapeutic Drug Monitoring May Be Future of Inflammatory Bowel Disease Management

Therapeutic drug monitoring is a growing and vital area for pharmacists to become involved in to increase patient success with inflammatory bowel disease remission.

Big Health Expands into Adolescent Mental Health Through Acquisition of Limbix - Vimarsana News

Big Health Expands into Adolescent Mental Health Through Acquisition of Limbix

/PRNewswire/ -- Big Health, the leading provider of non-drug digital treatments for mental health, has acquired Limbix, creators of the first, evidence-based...

Low-dose atropine eyedrops no better than pla - Vimarsana News

Low-dose atropine eyedrops no better than pla

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, according to a randomized controlled trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the National Eye Institute (NEI). The trial aimed to identify an effective way to manage this leading and increasingly common cause of refractive error, which can cause serious uncorrectable vision loss later in life. Results from the trial were published in JAMA Ophthalmology.